English  |  正體中文  |  简体中文  |  Items with full text/Total items : 6024/14565 (41%)
Visitors : 13725321      Online Users : 297
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.fy.edu.tw:8080/ir/handle/987654321/18735


    Title: Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT
    Authors: Lin, Huey-Shyan;Lin, Ching-Hua
    Contributors: 輔英科技大學 健康事業管理系
    Keywords: Major depressive disorder;17-item Hamilton Depression Rating Scale;ResponseRemission;Early improvement
    Date: 2019-03-25
    Issue Date: 2019-08-26 14:30:54 (UTC+8)
    Abstract: Background
    : HAMD-6 is derived from the 17-item Hamilton Rating Scale for Depression (HAMD-17).We explore whether HAMD-6 is a reliable, valid, and sensitive to change measure, and whether early improvement using HAMD-6 can predict ultimate response/remission for inpatients with major depressive disorder (MDD) receiving either fluoxetine or electroconvulsive therapy (ECT).

    Methods
    : Data were from 2 trials for 126 MDD inpatients receiving fluoxetine, and 116 inpatients receiving ECT. Internal consistency, validity, and sensitivity to change using HAMD-17 and HAMD-6 at each assessment were examined and compared. Early improvement was defined as an at least 20% reduction of HAMD-17 or HAMD-6 scores at week 2 for patients receiving fluoxetine, or after 6 treatments for patients receiving ECT. Response was defined as ??50% HAMD-17 score improvement from baseline, and remission was defined as a total HAMD-17 score of ??7 at endpoint. Receiver operating characteristic analysis was used to determine which rating scale had better discriminative capacity.

    Results
    : HAMD-6 is a reliable, valid, and sensitive to change measure. Early improvement using HAMD-6 had comparable predictive values with that of HAMD-17 for response/remission for patients receiving either fluoxetine or ECT.

    Limitations
    : Samples were taken from 2 open-label trials with limited sample sizes.

    Conclusions
    : HAMD-6 is a clinically useful measure. Those patients without early improvement, however, have a minimal chance of reaching ultimate response/remission, regardless of whether HAMD-17 or HAMD-6 was use.
    Relation: Journal of Affective Disorders 245(15),91-97
    Appears in Collections:[健康事業管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML259View/Open


    All items in FYIR are protected by copyright, with all rights reserved.


    本網站典藏內容為學術研究目的之提供,請尊重著作權人之權益合理使用,請勿任意重製、轉貼、改作及散佈。

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback